In this issue:
- COVID-19’s impact on asthmatics
- Inflammatory mechanism of budesonide in early COVID-19
- Prevalence, deaths and DALYs due to asthma and its attributable risk factors
- Impact of prolonged bushfire smoke exposure in severe asthma
- Air pollutants and asthma hospitalisation in the US
- Violence-related distress and lung function in youth
- Barriers and enablers for personalised severe asthma care
- SABA prescriptions and clinical outcomes of asthma
- Positioning as-needed budesonide-formoterol for mild asthma
- Dose effect and time course of fluticasone furoate and fluticasone propionate in persistent asthma
- Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
- Azithromycin for poorly controlled asthma in children
- Anti-IL-5 minimally influences residual blood eosinophils in severe asthma
- Benralizumab effectiveness in severe asthma not affected by prior biologics
Please login below to download this issue (PDF)